Clinical trial
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
NCT04309084 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
- Lead sponsor
- Celularity Incorporated
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- May 12, 2020
- Completion date
- April 30, 2023
- Enrollment
- 29 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
analgesics, analgesics, non-narcotic, antineoplastic agents, blood protein disorders, cardiovascular diseases, hematologic diseases, hemorrhagic disorders, hemostatic disorder, immune system diseases, immunoproliferative disorders, lymphoproliferative disorders, multiple myeloma, neoplasm, plasma cell, neoplasms, neoplasms by histologic type, paraproteinemias, peripheral nervous system agents, physiological effects of drugs, sensory system agents, vascular diseases